Vimarsana
Biggest News Aggregation in the World

Page 2 - Avidity Analyzer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Avidity Analyzer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Avidity Analyzer Today - Breaking & Trending Today

LUMICKS Unveils Groundbreaking New C-Trap Product at Biophysical Society Annual Meeting - Vimarsana News

LUMICKS Unveils Groundbreaking New C-Trap Product at Biophysical Society Annual Meeting

New product line C-Trap 'Edge' brings unparalleled features relevant for surface assays, which are of increasing importance in biophysical and biological research AMSTERDAM, Feb. 22, 2022

New Nature Paper Relies on LUMICKS' C-Trap Technology to Understand Functionality of Key Protein Involved with Incorrect DNA Repair of Dangerous Lesions Linked to Cancer Predisposition - Vimarsana News

New Nature Paper Relies on LUMICKS' C-Trap Technology to Understand Functionality of Key Protein Involved with Incorrect DNA Repair of Dangerous Lesions Linked to Cancer Predisposition

AMSTERDAM, Feb. 15, 2022 /PRNewswire/ -- LUMICKS, a leading life science tools company that develops equipment for dynamic single-molecule and cell avidity analysis, today announced that its

LUMICKS: New study published in Translational Medicine highlights cell avidity's power as a functional biomarker for improved CAR-T design in preventing tumor escape - Vimarsana News

LUMICKS: New study published in Translational Medicine highlights cell avidity's power as a functional biomarker for improved CAR-T design in preventing tumor escape

AMSTERDAM, Jan. 25, 2022 /PRNewswire/ -- LUMICKS, a next generation life science tools company, today announced that research findings from a consortium, led by researchers at Cancer Center

LUMICKS Raises $93 Million in Series D Financing - Vimarsana News

LUMICKS Raises $93 Million in Series D Financing

LUMICKS Raises $93 Million in Series D Financing - Backed by global investor syndicate led by new investors Farallon Capital Management and Lauxera Capital Partners along with Softbank Fund 2, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Gilde Healthcare, Pura Vida Investments, and Irving Investors AMSTERDAM, April 16, 2021 /PRNewswire/ -- LUMICKS, a leading, next-generation life science tools company that develops highly innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced the completion of a $93 million Series D preferred...